Our jury

In 2019, 42plus1 was launched to support the best entrepreneurial talents and help to secure funding. Together with our jury of venture capitalist, successful founders, leading academic and industry partners, we bring the best startups to success.

Our confirmed jurors for the 42plus1 finals at DxPx 2022 on November 16th in Düsseldorf

The finalist will pitch infront of a jury of at least 8 VCs from around the world – and a live audience of several 100 industry experts.
Bernd Goergen​

Bernd Goergen

Partner, High-Tech Gründerfonds

Rainer Christine

Rainer Christine

Partner, Earlybird Venture Capital

Wouter Meuleman

Partner, Illumina Ventures

Tom Miller

Tom Miller

Founder & Managing Partner, Greybird Ventures
Sebastian Stamm

Sebastian Stamm

Principal, FluxUnit
Tobias Silberzahn

Tobias Silberzahn

Partner, McKinsey & Company
Douwe Jippes

Douwe Jippes

Founder & Managing Partner, Healthy Capital
Sascha Fritz

Sascha Fritz

Investment Principal, Bosch
Dr. Jens Baas

Dr. Jens Baas

Founder & CEO, Techniker Krankenkasse
Dr. Mirko Stange

Dr. Mirko Stange

Initator of DxPx, lino Biotech
Dirk Voelkel

Dirk Voelkel

Vice President Innovation, Cytiva
André Zimmermann

André Zimmermann

Partner, SHS Capital
More jurors will be posted prior the event.

Meet our investors who evaluate all incoming applications!

A new European fund investing in early-stage therapeutics, medtech and bio-IT companies in the US and Europe.
As a company, Coelum AG has founded or acquired several companies and set them on the road to success
Earlybird is a venture capital investor focused on European technology innovators.
We are expert consultants for the in vitro diagnostic industry. Point of care, biomarkers, cardiac, infectious diseases, cancer.
We invest in innovative early stage Life Sciences startups that address unmet needs with novel discoveries backed by strong science and competitive advantage over current options.
We are i&i Prague, a biotech hub located right in the centre of Europe, and our objective is to identify the potential of, and nurture, new inventions in MedTech, Biotech, Diagnostics and Drug Discovery by Central European scientists and researchers.
IPF Partners is a leading alternative financing provider focused on the healthcare sector.
We understand the needs of science and tech based startups and help you to grow and thrive.
Karista is an early-stage venture capital firm founded in 2001 investing in Health, Digital, Tech, and NewSpace.
We invest at various stages of maturity from company creation to capital expansion.
Limerston Capital is a private equity firm with over £300 million under management. We target UK businesses valued at £20 – £200 million, partnering with management teams to help build them into industry leaders.
As an independant multi-stage investor, we find constant inspiration in entrepreneurs’ endeavours and desire for growth.
Novalis Biotech is an early stage venture capital investor in life sciences.
Our NRW.Venture team supports start-ups in the development and marketing of innovative technologies and business models and the rapid expansion of their business.
Venture Capital funding for dynamic startups and young emerging companies.
Increase health, improve energy efficiency, ensure safety & comfort – for a better tomorrow.